Ivabradine use was associated with a reduction of the primary composite endpoint in patients both with ( HR @ , P = @ ) and without renal dysfunction ( HR @ , P < @ ) at baseline ( P for interaction = @ ) , and tolerability of ivabradine was comparable in the two groups .